Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
Raja Mudad,1 Manish B Patel,2 Sandra Margunato-Debay,2 David Garofalo,3 Lincy S Lal4 1University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Hollywood, FL, USA; 2Celgene Corporation, Summit, NJ, USA; 3Cardinal Health, Dallas, TX, USA; 4University of Texas School of Pub...
Main Authors: | Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-10-01
|
Series: | Lung Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/comparative-effectiveness-and-safety-of-nab-paclitaxel-plus-carboplati-peer-reviewed-article-LCTT |
Similar Items
-
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
by: Tobias Dechow, et al.
Published: (2021-11-01) -
Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01) -
Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer
by: HOU Wenjie, et al.
Published: (2018-06-01) -
Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01) -
Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)